Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Torii: Declines in Sales and Profits
May 29, 2006
- JGPMA to Propose "Drug Benefit Standard Prices System"
May 29, 2006
- Banyu to Re-launch Nu-lotan
May 29, 2006
- ASKA: Higher Cost Ratio Results in Profit Slump
May 29, 2006
- GENERIC NEWS IN BRIEF
May 29, 2006
- Combined Sales, Profits of Top 10 Companies Up in FY2005
May 29, 2006
- Toyama Chemical: Pharma Div. Sales Down 8.4%
May 29, 2006
- Metabolic Syndrome Estimated to Affect 9.4 Mil. Japanese Over 40
May 29, 2006
- Astellas: Stronger Sales, Profits Driven by Overseas Growth
May 29, 2006
- Seikagaku Corp.: Good US Sales Prop Up Business
May 29, 2006
- Eisai: Another Year of Record Sales and Profits
May 29, 2006
- Kirin: Pharma Division Posts 14.5% Growth in Sales
May 29, 2006
- Taisho: Pharma Sales Up 0.6%, Self-medication Sales Down 4.7%
May 29, 2006
- JT: New 3-Year Management Plan Aimed at Long-term Growth
May 29, 2006
- Shionogi: Royalties Prop Up Profits Despite Lower Sales
May 29, 2006
- Industry Should Oppose Unreasonable Proposals: New FPMAJ President
May 29, 2006
- Mr T. Korekane Appointed President: Ono
May 29, 2006
- So-net M3 Starts Trial Run of "Doctors Blog"
May 29, 2006
- Santen: Ethical Drug Sales Up Domestically and Overseas
May 29, 2006
- STATISTICS
May 29, 2006
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…